Cardiovascular Outcomes Registry in Cardiogenic SHOCK (COR-SHOCK)
Cardiovascular Outcomes Registry in Cardiogenic SHOCK
Hospital de Santa Cruz, Portugal
800 participants
Jun 10, 2026
OBSERVATIONAL
Conditions
Summary
The goal of this observational study is to evaluate the clinical outcomes and management approaches of cardiogenic shock throughout the years in adult patients admitted to a Cardiology Department. The main questions it aims to answer are: * How have management strategies and clinical outcomes for cardiogenic shock evolved over time? * How do clinical, laboratory, and advanced hemodynamic monitoring parameters relate to patient survival and overall prognosis in this population? Researchers will evaluate clinical data collected from 2017 onwards to see if therapeutic advancements and changes in clinical management over the years have led to improved patient survival and quality of care. Participants will: * Receive standard, routine medical care for cardiogenic shock as determined by their clinical team (no experimental interventions will be introduced). * Have their clinical, laboratory, and imaging data collected from hospital electronic records during their stay. * Be followed for up to 1 year after hospital admission to evaluate long-term survival and clinical outcomes.
Eligibility
Inclusion Criteria13
- Cardiogenic shock according to the following criteria:
- Cardiac disorder resulting in hypotension, defined as at least one of the following:
- Systolic blood pressure (SBP) <90 mmHg for ≥30 minutes, or
- Requirement for vasopressors, inotropes, or mechanical circulatory support to maintain SBP ≥90 mmHg
- AND
- Evidence of tissue hypoperfusion, defined by the presence of at least one of the following:
- Serum lactate >2 mmol/L
- Acute kidney injury and/or oliguria
- Acute hepatic injury
- Cool or mottled extremities
- Altered mental status
- AND
- Clinical presentation judged to be primarily attributable to a cardiac etiology.
Exclusion Criteria3
- Age < 18 years.
- Other primary etiologies of shock at presentation (e.g., hypovolemic, hemorrhagic, septic, obstructive shock due to acute pulmonary embolism, or anaphylactic shock).
- Refusal to participate in the study (applicable only to the prospective cohort).
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07597291